A clinical trial conducted by Wei et al. [67] involving 36 participants (18–75 years old) with hyperlipidemia explored the effects of the administration of PSO capsules (4 grain/time, twice/day) on serum lipid and C-reactive protein (CRP) levels. The gene discussed is CRP; the disease is hyperlipidemia.